

1 **Single-cell RNA-seq and V(D)J profiling of immune cells in** 2 **COVID-19 patients**

3
4 Xiaoying Fan^{1,#}, Xiangyang Chi^{2,#}, Wenji Ma^{3,#}, Suijuan Zhong^{4,#}, Yunzhu Dong^{2,#},
5 Wei Zhou¹, Wenyu Ding⁴, Hongyan Fan⁵, Chonghai Yin³, Zhentao Zuo³, Yilong Yang²,
6 Mengyao Zhang², Qiang Ma^{3,6}, Jianwei Liu¹, Ting Fang², Qian Wu^{4,*}, Wei Chen^{2,*},
7 Xiaoqun Wang^{1,3,6,7,*}

8
9 ¹Guangzhou Regenerative Medicine and Health Guangdong Laboratory, 510005
10 Guangzhou, China

11 ²Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS),
12 Beijing 100071, China

13 ³State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in
14 Brain Science and Intelligence Technology, Institute of Brain-Intelligence Technology
15 (Shanghai), Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101,
16 China.

17 ⁴State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal
18 University, Beijing, 100875, China

19 ⁵Department of Clinical Laboratory, The 940th Hospital of PLA Joint Logistics Support
20 Forces

21 ⁶University of Chinese Academy of Sciences, Beijing 100049, China

22 ⁷Advanced Innovation Center for Human Brain Protection, Beijing Institute for Brain
23 Disorders, Capital Medical University, Beijing, 100069, China

24
25 #These authors contributed equally

26 *Corresponding authors: Wei Chen (cw0226@foxmail.com), Qian Wu
27 (qianwu@bnu.edu.cn), Xiaoqun Wang (xiaoqunwang@ibp.ac.cn)

28
29
30
31
32
33
34 **Keywords:** Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome
35 coronavirus 2 (SARS-CoV-2); T lymphocytes; B lymphocytes; Single-cell RNA
36 sequencing (scRNA-seq); V(D)J sequencing; TCR; BCR

41 **Abstract**

42 Coronavirus disease 2019 (COVID-19) has caused over 220,000 deaths so far and is
43 still an ongoing global health problem. However, the immunopathological changes of
44 key types of immune cells during and after virus infection remain unclear. Here, we
45 enriched CD3⁺ and CD19⁺ lymphocytes from peripheral blood mononuclear cells of
46 COVID-19 patients (severe patients and recovered patients at early or late stages) and
47 healthy people (SARS-CoV-2 negative) and revealed transcriptional profiles and
48 changes in these lymphocytes by comprehensive single-cell transcriptome and V(D)J
49 recombination analyses. We found that although the T lymphocytes were decreased in
50 the blood of patients with virus infection, the remaining T cells still highly expressed
51 inflammatory genes and persisted for a while after recovery in patients. We also
52 observed the potential transition from effector CD8 T cells to central memory T cells in
53 recovered patients at the late stage. Among B lymphocytes, we analyzed the expansion
54 trajectory of a subtype of plasma cells in severe COVID-19 patients and traced the
55 source as atypical memory B cells (AMBCs). Additional BCR and TCR analyses
56 revealed a high level of clonal expansion in patients with severe COVID-19, especially
57 of B lymphocytes, and the clonally expanded B cells highly expressed genes related to
58 inflammatory responses and lymphocyte activation. V-J gene usage and clonal types of
59 higher frequency in COVID-19 patients were also summarized. Taken together, our
60 results provide crucial insights into the immune response against patients with severe
61 COVID-19 and recovered patients and valuable information for the development of
62 vaccines and therapeutic strategies.

63

64

65

66

67

68

69

70

71

72

73 **Main**

74 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally to
75 cause the coronavirus disease 2019 (COVID-19) pandemic and over 240,000 deaths,
76 and the number of cases of infection and death are still rising rapidly. Patients with
77 COVID-19 typically exhibit symptoms of fever, dry cough, fatigue, difficulty breathing,
78 headache, diarrhea, nausea, muscle and/or joint pain, pneumonia, etc¹⁻⁴. Some severe
79 COVID-19 cases include development of acute respiratory distress syndrome (ARDS)
80 and damage to multiple organs^{1,4-6}. The rapidly developing single-cell sequencing
81 technologies provide powerful tools for exploring immune cell heterogeneity as well as
82 immunotherapy and drug discoveries⁷⁻⁹. Here, to investigate what roles lymphocytes
83 play in defending against SARS-CoV-2 viral infections, we recruited 13 participants.
84 In addition to 4 patients with severe symptoms, we also included 6 cured patients and
85 3 healthy people who were negative for the SARS-CoV-2 virus tests. Peripheral blood
86 mononuclear cells (PBMCs) of each individual were isolated from whole blood, and
87 magnetic separation was used to collect CD3-positive cells or CD19-positive cells to
88 enrich the T lymphocyte or B lymphocyte populations, respectively, from PBMCs.
89 Based on the timing of blood collection, the 6 recovered patients were divided into 2
90 groups: the blood samples of 3 patients were collected within one week after the
91 diagnosis with negative results of the SARS-CoV-2 virus test and no clinical symptoms
92 (which were categorized as recovered patients at the early stage (RE patients)), while
93 the blood samples of the other 3 cured patients were collected 20 days after a negative
94 diagnosis and hospital discharge (which were named recovered patients at the later
95 stage (RL patients)). After CD3 or CD19 antibody selection using MCS separation,
96 single-cell mRNA transcriptome and single-cell V(D)J sequences of T lymphocytes and
97 B lymphocytes were collected and analyzed. In total, we obtained scRNA-seq (single-
98 cell RNA-sequencing) data from 70,984 cells and V(D)J combination information from
99 24,307 T lymphocytes and 46,689 B lymphocytes. A total of 42,791 cells (15,134 T
100 lymphocytes and 27,657 B lymphocytes) were identified with matched gene expression
101 and V(D)J combination profiles at the single-cell level.

102 We first performed unbiased clustering of the single-cell mRNA profiles and

103 identified 38 clusters, which could be categorized into 18 cell types (Fig. 1a-c, S1a).
104 There were 9 classes of T lymphocytes (*CD3E*⁺) identified, including 4 subtypes of
105 *CD4*⁺ T cells (11,961 cells) and 5 subtypes of *CD8*⁺ T cells (17,683 cells) (Fig. 1a, b).
106 Interestingly, we observed that the percentage of T cells was decreased in SARS-CoV-
107 2-infected individuals, especially in patients with severe symptoms, compared with
108 uninfected individuals (Fig S1b). For the B lymphocytes, we identified 4 *CD19*⁺ and
109 *CD79A*⁺ classes: B cells (22,728 cells), memory B cells (5,617 cells), plasma B cell
110 (2,284 cells) and plasmablasts (698 cells) (Fig 1a-c). In addition to T and B lymphocytes,
111 we also picked up some other types of PBMCs, including monocytes (7,508 *CD14*⁺
112 monocytes and 777 *FCGR3A*⁺ monocytes), dendritic cells (130 cells), natural killer
113 (NK) cells (1,282 cells), and platelets (316 cells) (Fig. 1a-c, S2). These cell types
114 showed a similar number of detected genes, except for platelets (Fig. S1c). The cells
115 from the samples of the same group (healthy, RE, RL and severe groups) showed similar
116 distributions, suggesting that patients at similar stages after virus infection might
117 experience similar immune responses (Fig. S3a). Intriguingly, we observed enrichment
118 of some cell types in some sample groups (Fig 1d, e, S3b). For example, the two types
119 of T helper cells, which are reported to have different immune responses, showed
120 distinct proportions in the four groups; specifically, Th2-like follicular helper (Tfh)
121 cells (*ICOS*⁺), which specialize in activating B cells to produce antibodies for immune
122 responses in defending the body from extracellular pathogens¹⁰, were largely enriched
123 in recovered patients, especially in the RE samples (Fig 1e, S3b). While Th1 cells,
124 which are responsible for cell-mediated immunity by activating macrophages¹⁰, showed
125 a larger population in RL samples than in the other sample types, reduced populations
126 of both types of T helper cells were detected in patients experiencing severe virus
127 infection (Fig. S3b). Accordingly, the majority of B lymphocytes in RE samples were
128 B cells (Fig S3b). The majority of plasma B cells (85.4%), which are responsible for
129 antibody production in an effective immune response, in patients with severe clinical
130 features (Fig 1d, e, S3b).

131 To further investigate how T cells responded to SARS-CoV-2 virus infection, we first
132 compared the T cell subclusters (Fig. S4a). We found that the 15 subclusters of T cells

133 could be grouped into 5 modules based on the highly variable genes in the T cell
134 transcriptomic profiles rather than on patient groups (Fig. S4a, b). Then, we analyzed
135 the differentially expressed genes (DEGs) of T cells from different patient groups (Fig.
136 2a). We found that inflammatory genes, including *IFNG* (interferon gamma), *CD160*,
137 *S100A8* and *GZMA*, were highly expressed by T cells from patients with severe
138 infection, indicating that T cells were highly activated to participate in the response
139 against virus infection in these patients (Fig. 2a-d). Accordingly, gene ontology (GO)
140 analysis of the DEGs suggested that cytokine production and immune response-related
141 leukocyte activation may occur in COVID-19 patients with severe symptoms (Fig. 2b).
142 Interestingly, T cells from RE patients highly expressed *RNF125*, *CXCR4*, and *PEL11*,
143 indicative of T cell activation still existing even after recovery at early time, which is
144 consistent with the GO analysis results.

145 Since CD8⁺ T cells, also known as cytotoxic T cells, play essential roles in
146 recognizing, binding and killing cells when infected by viruses¹¹, we determined the
147 differentiation trajectories of the CD8⁺ T cells by monocle analysis¹² (Fig. 2e, S5a). We
148 found that the cells started from naïve CD8 T cells and then developed into central
149 memory CD8 T, effector CD8 T and effector memory CD8 T cells, mirroring the classic
150 CD8 T cell differentiation process activated by confrontation with pathogens.
151 Intriguingly, we found two subgroups of naïve CD8 T cells (clusters 8 and 26) located
152 in two different branches on the trajectory path, and their cell composition differed
153 remarkably. The majority of cluster 8 cells were from the healthy group, while cluster
154 26 cells were predominantly from the RL group (Fig. 2e) and highly expressed *IL7R*,
155 which is a receptor of IL7 and plays roles in early T cell development, homeostasis and
156 activation. This indicated that naïve CD8 T cells from recovered patients may be at
157 different states with specific transcriptome profiles (Fig S4c). Additionally, most central
158 memory CD8 T cells were from healthy samples (41.4%), while most effector memory
159 CD8 T cells (57.6%) were from RL samples, indicating that recovered patients probably
160 have a recent memory of immune responses induced by SARS-CoV-2 infection. Next,
161 we further analyzed the DEGs of effector CD8 T cells based on patient groups (Fig. 2f,
162 g). The effector CD8 T cells from severe samples highly expressed *PTGDR*, which has

163 been identified as a mediator of allergic airway inflammation¹³, and *GZMK*, *XCL2*,
164 which were highly expressed in activated T cells, indicating that effector CD8 T cells
165 were highly active in disease conditions. Additionally, *CXCR4* and *RNF125*, which play
166 roles in T cell migration, maintenance and activation, were expressed by CD8 T cells
167 from the RE group but not by those from the RL group (Fig. 2f, g), suggesting that
168 inflammatory responses are still active when SARS-CoV-2 virus is eliminated. We also
169 found that *CCR7* and *SELL* were relatively highly expressed by effector CD8 T cells
170 from RL samples compared to those from other groups, indicating that these T cells
171 may be at the point to transition into central memory T cells for long-term immune
172 protection.

173 CD4⁺ T cells play critical roles in activating the cells of the innate immune system,
174 B lymphocytes, and cytotoxic T cells for the immune response. We next analyzed DEGs
175 of CD4⁺ T cell subtypes, including 2 subclusters of naïve CD4 T cells (clusters 4 and
176 6), and subclusters of Th1, Th2-like Tfh and Treg cells (Fig. 2h). The naïve CD4 T cells
177 of cluster 6 and cluster 4 highly expressed genes related to cell adhesion/migration and
178 positive regulation of cell killing, respectively, indicating that the two subgroups of
179 naïve CD4 T cells may be in different states (Fig. 2h). Consistently, cluster 6 was
180 enriched for naïve CD4 T cells from samples from recovered patients at late stages, and
181 cluster 4 cells were dominantly from samples from recovered patients at early stages
182 (Fig. S4a, b), indicating that some naïve CD4 T cells in the RE samples may have still
183 been transitioning into T helper cells to participate in protection.

184 Although we used magnetic beads to enrich CD3⁺ and CD19⁺ lymphocytes, we still
185 captured 8,285 monocyte, which were categorized as classical *CD14*⁺ monocyte and
186 non-classical *FCGR3A* (*CD16*)⁺ monocyte (Fig 2i). The subclusters of monocytes
187 showed distinct gene expression patterns that correlated with the status of SARS-CoV-
188 2 infection (Fig. 2i, S5b). In *CD14*⁺ monocyte, almost all cluster 22 cells (1,328/1,334)
189 were from severe samples with high expression of *KLF6* and *IL1R2* (Fig 2i). As
190 monocyte play a crucial role in the elimination of pathogens, which are activated by
191 Th1 cells, we next analyzed the ligand-receptor reactions between Th1 cells and
192 monocyte during defense against the virus. Cell-cell communication analysis of Th1

193 cells (ligands) and CD14⁺ monocytes (receptors) between the severe and other groups
194 (healthy, RE, and RL groups) (Fig 2j) revealed that inflammatory signals *S100A8* and
195 *IL1B*, *IL1RN*, and *IL16* on Th1 cells have stronger interaction with *ANXA2* and *IL1R2*
196 on CD14⁺ monocyte, respectively, while *CCL3/CCL5-CXCR4*-mediated signals and
197 *TGFBI* signals were decreased in severe samples (Fig. 2j).

198 Together, these results show that although the numbers of T cells in the peripheral
199 blood were reduced upon infection with the SARS-CoV-2 virus, the remaining T cells,
200 especially CD8⁺ cytotoxic T cells, were activated, and their activities lasted for a while
201 after recovery in patients, indicating that CD8⁺ T cells in the peripheral blood of
202 COVID-19 patients play an important role in the immune response to the virus. We also
203 observed a trend of transition from effector CD8 T cells to central memory T cells in
204 recovered patients, which may be prepared for future protection from the SARS-CoV-
205 2 virus.

206 B lymphocytes function in the humoral immunity component of the adaptive immune
207 system by secreting the specific antibody to bind an antigen¹⁴. A total of 14 subtypes of
208 B lymphocytes (including 9 clusters of B cells, 2 clusters of memory B cells, 2 clusters
209 of plasma B cells and 1 cluster of plasmablasts) were grouped into 2 modules based on
210 cell identities (Fig. 2k, l, S6a). We next examined the different subtypes of B cells (Fig.
211 2m). Clusters 0, 1, 12, 15, and 30 highly expressed the naïve B cell genes *BACH2* and
212 *CD38*, while *CD80*, *CD86* and *CXCR3* were relatively highly expressed in clusters 2
213 and 38, indicating that these B cells may be activated. Notably, we found that the B
214 cells of cluster 14 highly expressed *TBX21*, *FCRL5*, and *ITGAX*, marker genes of
215 atypical memory B cells (AMBCs), which are induced by specific types of virus
216 infection¹⁵.

217 In B cells, we found that the composition of each cluster differed in terms of infection
218 status (Fig. 2l). To further explore the gene expression differences of B cells in the
219 various COVID-19-related states, we next analyzed the DEGs and GO terms of virus-
220 infected and healthy people (Fig2n, o, S6b). We found that genes playing roles in the
221 response to viruses, the regulation of cytokine production, and apoptosis were enriched
222 in patients with severe conditions (Fig. 2o). In addition, GO analysis indicated that the

223 *IL12* signaling pathway was involved in regulating B cells in severe and recovered
224 patients at the late stage (Fig. 2o). Genes related to natural killer cell activation and
225 antigen processing and presentation were relatively enriched in B cells from samples
226 taken from patients with severe symptoms, which is consistent with our observation
227 that plasma B cells were high in that group (Fig 2o). Th2-like Tfh cells are considered
228 to facilitate B cell activation by releasing inflammatory signals or via ligand-receptor
229 interactions. Therefore, we further analyzed the ligand-receptor interactions between
230 Th2-like Tfh cells and B cells among different groups (Fig S6c). Similar expression and
231 interaction patterns of classical interleukins, such as *IL2*, *IL4*, *IL7*, and *IL10*, were
232 observed among groups. However, cell-cell communications through *TNF* and
233 chemokine signals differed among groups, indicating that Tfh cells may regulate B cells
234 in a slightly different way at different stages of the immune response against SARS-
235 CoV-2 (Fig S6c).

236 T cell receptor (TCR) and B cell receptor (BCR) characteristics are crucial for
237 analyzing the T cell repertoires and B cell repertoires within samples from patients
238 infected by SARS-CoV-2¹⁶. Thus, we explored the single-cell TCR and BCR V(D)J
239 data in each group of samples. Interestingly, although the individuals with SARS-CoV-
240 2 infection showed a reduced number of lymphocytes (Fig. S1b), we observed a high
241 level of clonal expansion in both the TCR and BCR repertoires in severe samples,
242 especially for the BCR repertoire (Fig. 3a, S7, S8). To understand the differences
243 between expanding and nonexpanding B lymphocytes in response to virus, we further
244 divided the B lymphocytes into monoclonal B lymphocytes and clonally expanded B
245 lymphocytes. Transcriptome correlation analysis indicated that the monoclonal B
246 lymphocytes in the four groups were similar, while the clonally expanded B
247 lymphocytes were heterogeneous (Fig. 3b). We further analyzed the DEGs of the two
248 types of B lymphocytes in patients with severe infection (Fig 3c). The clonally
249 expanded B lymphocytes highly expressed *CD27*, *CD38*, *XBPI*, *MZB1*, *IFI6*, and
250 *TNRSF17*, indicating activation and the effector functions of these B cells. To explore
251 the preferential V and J combinations in COVID-19 patients, we first analyzed and
252 listed the V and J combinations most frequently used in the BCRs and TCRs in all

253 samples (Fig. 3d-e). Among these combinations, relatively frequent pairings of the BCR
254 in RE patients were IGKV1-9::IGKJ4, IGHV2-70::IGHJ4 and IGHV3-33::IGHJ2,
255 and the IGKV3-15::IGKJ1, IGHV3-53::IGHJ4, IGHV3-33::IGHJ1 and
256 IGHV1-69::IGHJ4 combinations were frequent in RL patients. (Fig. 3d). In addition to
257 these highly used pairs, IGLV2-23::IGLJ6 was a unique combination in severe COVID-
258 19 patients (Fig 3d). Additionally, the TCR pairings with the highest frequencies in
259 samples from early recovered patients were TRBV18::TRBJ1-1, TRBV4-1::TRBJ2-7,
260 TRBV6-1::TRBJ1-5, TRAV14/DV4::TRAJ29, and TRBV20-1::TRBJ1-6, among
261 others (Fig. 3e). We next compared the usage of BCR and TCR V(D)J genes in COVID-
262 19 patients with that in healthy people (Fig. 3f, g). We identified a relatively high usage
263 of IGHJ6, IGHV3-30, IGHV3-33, IGHV-40-2, IGKJ2, IGKV1D-39, and IGKV4-1 in
264 COVID-19 patients compared to healthy people (Fig. 3f). We then analyzed and
265 revealed the amino acid sequences of the CDR3 gene in high-frequency TCR clones in
266 different samples (Fig. 3h). These recognition sequences may have special functions
267 during SARS-CoV-2 infection.

268 Since we had both scRNA-seq transcriptome and TCR/BCR data, we next integrated
269 and analyzed 42,791 cells (15,134 T lymphocytes and 27,657 B lymphocytes) with both
270 types of information. All lymphocytes showed different degrees of clone expansion,
271 and the effector CD8 T cells of severe COVID-19 patients showed relatively high clone
272 numbers (Fig. 4a, b, S9). The plasmablast and plasma B cells in severe COVID-19
273 patients showed the highest degree of clonal expansion, indicating that SARS-CoV-2
274 infection may induce B cells to differentiate into plasma B cells to secrete antibodies
275 against the virus. Hence, we analyzed the developmental trajectory of plasmablast and
276 plasma B to trace the cell lineage. Interestingly, we found that plasmablast differentiated
277 in two directions (cluster 17 and cluster 32) with distinct gene expression patterns (Fig.
278 4c, d). A total of 98.8% of the plasma B cells of cluster 17 were from severe COVID-
279 19 patients, while cluster 32 consisted of plasma B cells from all groups (Fig. 2m). The
280 tracing of BCR clones revealed a preferential differentiation of plasmablast into plasma
281 B cells during SARS-CoV-2 infection (Fig. 4c). Further comparison of the two clusters
282 of plasma B cells revealed that cells of cluster 17 highly expressed *FOS*, *IFI6*, *IGLL5*

283 and *MXI*, indicating that these cells were activated (Fig. 4d). Importantly, we traced the
284 source of these active plasma B cells as AMBCs (cluster 14 B cells) with a specific
285 clonotype, indicating the important role of AMBCs in the immune response to SARS-
286 CoV-2. Together, these findings show that the BCR clonotypes enriched in the plasma
287 B cells might be helpful for vaccine and antibody production.

288 COVID-19 patients sometimes experience a cytokine storm, which forces the
289 patient's immune system into overdrive and can lead to death^{17,18}. Therefore, we next
290 focused on the global expression of cytokines in different cell types under various
291 COVID-19-related statuses (Fig. 4e). *IL1A* and *IL1B* expression was high in *FCGR3A*+
292 monocytes from severe COVID-19 patients. *IL6*, an inhibitor of which has been shown
293 to ameliorate severe symptoms caused by cytokine release in patients with SARS-CoV-
294 2 infections, was highly expressed by B cells, especially those from severe samples.
295 Interestingly, recovered patients also have high expression of some interleukin
296 molecules. We found that *IL12A* was high in B cells, memory B cells and plasma B
297 cells from RE samples. *IL16* was highly expressed by effector memory CD8 T cells,
298 naïve CD4 T cells, proliferating CD8 T cells and plasma B cells from RL samples. In
299 addition to interleukins, *IFNG*, which is crucial for immunity against intracellular
300 pathogens, was highly expressed by many types of CD8 T cells (effector CD8 T,
301 effector memory CD8 T, naïve CD8 T and proliferating CD8 T cells) from severe
302 patients. In addition, *TNF* (tumor necrosis factor), as an activator of the immune system,
303 was highly expressed by monocytes and central memory CD8 T cells from RL samples.
304 In terms of the expression pattern of chemokines, *IL8/CXCL8* expression was high in
305 monocytes, Th1 cells and proliferating CD8 T cells from severe samples. *CXCL2* was
306 generally expressed by classical and non-classical monocytes as well as Th1 cells from
307 infected and recovered samples. Overall, the differential expression of interleukins,
308 interferons, growth factors and chemokines in different types of cells in different
309 SARS-CoV-2 infection conditions suggests that the immune system might work in
310 slightly different ways in patients during infection and recovery at early or late stages.

311 In summary, we have illustrated changes in lymphocyte characteristics, including cell
312 type, inflammatory status, gene expression and V(D)J recombination sequence, upon

313 SARS-CoV-2 infection and after recovery. Coordinated and effective responses by
314 innate and adaptive immune cells are crucial for body protection and virus clearance.
315 Our results have revealed an active inflammatory response not only in severe COVID-
316 19 patients but also in recovered patients at an early stage (within one week after
317 diagnosis with negative results of the SARS-CoV-2 virus test). Lymphopenia is a
318 common feature in severe COVID-19 patients, including decreased CD4⁺ T cells,
319 CD8⁺ T cells, B cells and natural killer (NK) cells ^{4,19,20}. In our study, we found that
320 the proportion of T cells was reduced whereas the monocyte ratio was increased in
321 severe COVID-19 patients compared to healthy people. However, CD8⁺ T cells, which
322 are crucial for directly attacking and killing virus-infected cells, were active and highly
323 expressed inflammatory genes, such as *GZMA* and *INF*, in severe COVID-19 patients
324 as well as RE patients. Studies have revealed that patients who recovered from SARS
325 developed specific memory T cells, which were still detectable up to 2 years after
326 recovery^{21,22}. Our results indicate that a group of effector CD8⁺ T cells may be at the
327 stage of the process of transforming into central memory T cells in recovered patients
328 at late stage (20 days after diagnosis with negative results of the SARS-CoV-2 virus
329 test). It is very possible that these memory T cells could be vital for protecting these
330 people from SARS-CoV-2 virus reinfection.

331 B cell responses accompanied by CD4⁺ T follicular helper cell responses were
332 observed in COVID-19 patients. In B cells, genes related to the response to viruses, the
333 regulation of cytokine production, and apoptosis were enriched the most in patients
334 with severe infection and to a slightly lower degree in recovered patients. Consistent
335 with the high ratio of plasma cells in severe patients, genes related to antigen processing
336 and presentation were also highly expressed in B lymphocytes of these patients. The
337 plasma cells of COVID-19 patients exhibited highly expanded clones. Notably, when
338 tracing the BCR clones, we found that the source of a subtype of plasma cells in severe
339 COVID-19 patients was atypical memory B cells (AMBCs), which are a unique
340 subcluster of B lymphocytes, indicating that the B cells were highly active in the
341 immune response against SARS-CoV-2. Recent studies have suggested that antibody-
342 dependent enhancement (ADE) might be induced by SARS-CoV-2 infection in some

343 cases²³. Our results cannot determine whether ADE occurred in the patients with severe
344 infection involved in this study. In the clinic, convalescent plasma has been used for the
345 treatment of COVID-19, which potentially offers specific anti-SARS-CoV-2 polyclonal
346 antibodies and has some positive impacts on patients^{24,25}. Recent studies have reported
347 that it is very likely that a subset of patients may not develop long-lasting antibodies to
348 SARS-CoV-2. In our study, the numbers of plasma cells from recovered patients were
349 quite limited. Whether these recovered patients are able to produce an immune response
350 against future SARS-CoV-2 encounters needs further investigation.

351 One function of the adaptive immune system is recognizing and remembering
352 specific pathogens through T cell responses and antibodies produced by plasma
353 cells^{26,27}. Since COVID-19 is a pandemic, many efforts are underway to develop
354 therapeutic approaches against SARS-CoV-2 worldwide. One strategy is inducing
355 SARS-CoV-2-specific memory CD8 T cells from a vaccination. These memory CD8 T
356 cells can differentiate into effector T cells to kill infected cells before they produce
357 mature virions when the body is truly attacked by SARS-CoV-2. Another strategy is to
358 develop therapeutic antibodies against SARS-CoV-2 using BCR sequences from
359 recovered patients^{16,27-31}. We analyzed the characteristics of TCRs and BCRs from
360 patients with severe infection and patients who had recovered and revealed the cell-
361 type specific V(D)J sequences enriched in each group. This information provides
362 valuable resources for the development of vaccines and antibodies for COVID-19
363 immunotherapies.

364

365 **Acknowledgements**

366 This work was supported by the special project for COVID-19 of Guangzhou
367 Regenerative Medicine and Health Guangdong Laboratory (2020GZR110106009),
368 National Basic Research Program of China (2019YFA0110100).

369

370

371 **Author Contributions**

372 W. C, Q.W., X.W. and X. F. conceived the project, designed the experiments. X. C., Y,
373 D., L. Y. and M. Z. performed the sample preparation and single-cell RNA sequencing

374 experiment. H. F., T. F. and C. Y. helped on data transfer. X. F, W. M. and S. Z analyzed
375 the mRNA data. W. Z., W. D, Q. M. and J. L. analyzed the V(D)J data. W. Z., S. Z. and
376 Z. Z. performed clone tracing analysis. Q. W. and X. F wrote the manuscript. All authors
377 edited and proofed the manuscript.

378

379 **Competing interests**

380 The authors declare no competing interests.

381

382

383

384 **Reference**

- 385 1 Chan, J. F. *et al.* A familial cluster of pneumonia associated with the 2019 novel coronavirus
386 indicating person-to-person transmission: a study of a family cluster. *Lancet* **395**, 514-523,
387 doi:10.1016/S0140-6736(20)30154-9 (2020).
- 388 2 Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
389 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513,
390 doi:10.1016/S0140-6736(20)30211-7 (2020).
- 391 3 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J*
392 *Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 393 4 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
394 China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 395 5 Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
396 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, doi:10.1001/jama.2020.1585
397 (2020).
- 398 6 Young, B. E. *et al.* Epidemiologic Features and Clinical Course of Patients Infected With
399 SARS-CoV-2 in Singapore. *JAMA*, doi:10.1001/jama.2020.3204 (2020).
- 400 7 Giladi, A. & Amit, I. Single-Cell Genomics: A Stepping Stone for Future Immunology
401 Discoveries. *Cell* **172**, 14-21, doi:10.1016/j.cell.2017.11.011 (2018).
- 402 8 Ren, X., Kang, B. & Zhang, Z. Understanding tumor ecosystems by single-cell sequencing:
403 promises and limitations. *Genome Biol* **19**, 211, doi:10.1186/s13059-018-1593-z (2018).
- 404 9 Papalexli, E. & Satija, R. Single-cell RNA sequencing to explore immune cell heterogeneity.
405 *Nat Rev Immunol* **18**, 35-45, doi:10.1038/nri.2017.76 (2018).
- 406 10 Ruterbusch, M., Pruner, K. B., Shehata, L. & Pepper, M. In Vivo CD4(+) T Cell
407 Differentiation and Function: Revisiting the Th1/Th2 Paradigm. *Annu Rev Immunol* **38**, 705-
408 725, doi:10.1146/annurev-immunol-103019-085803 (2020).
- 409 11 Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune response to respiratory
410 coronaviruses. *Immunol Res* **59**, 118-128, doi:10.1007/s12026-014-8534-z (2014).
- 411 12 Qiu, X. *et al.* Reversed graph embedding resolves complex single-cell trajectories. *Nat*
412 *Methods* **14**, 979-982, doi:10.1038/nmeth.4402 (2017).
- 413 13 Oguma, T. *et al.* Role of prostanoid DP receptor variants in susceptibility to asthma. *N Engl J*
414 *Med* **351**, 1752-1763, doi:10.1056/NEJMoa031785 (2004).

- 415 14 LeBien, T. W. & Tedder, T. F. B lymphocytes: how they develop and function. *Blood* **112**,
416 1570-1580, doi:10.1182/blood-2008-02-078071 (2008).
- 417 15 Dauby, N. *et al.* Primary human cytomegalovirus infection induces the expansion of virus-
418 specific activated and atypical memory B cells. *J Infect Dis* **210**, 1275-1285,
419 doi:10.1093/infdis/jiu255 (2014).
- 420 16 Nielsen, S. C. A. & Boyd, S. D. Human adaptive immune receptor repertoire analysis-Past,
421 present, and future. *Immunol Rev* **284**, 9-23, doi:10.1111/imr.12667 (2018).
- 422 17 Xu, X. *et al.* Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl*
423 *Acad Sci U S A*, doi:10.1073/pnas.2005615117 (2020).
- 424 18 Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the 'Cytokine Storm' in
425 COVID-19. *J Infect*, doi:10.1016/j.jinf.2020.03.037 (2020).
- 426 19 Qin, C. *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan, China.
427 *Clin Infect Dis*, doi:10.1093/cid/ciaa248 (2020).
- 428 20 Xu, Z. *et al.* Pathological findings of COVID-19 associated with acute respiratory distress
429 syndrome. *Lancet Respir Med* **8**, 420-422, doi:10.1016/S2213-2600(20)30076-X (2020).
- 430 21 Libraty, D. H., O'Neil, K. M., Baker, L. M., Acosta, L. P. & Olveda, R. M. Human CD4(+)
431 memory T-lymphocyte responses to SARS coronavirus infection. *Virology* **368**, 317-321,
432 doi:10.1016/j.virol.2007.07.015 (2007).
- 433 22 Yang, L. T. *et al.* Long-lived effector/central memory T-cell responses to severe acute
434 respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. *Clin*
435 *Immunol* **120**, 171-178, doi:10.1016/j.clim.2006.05.002 (2006).
- 436 23 Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease
437 2019. *Clin Infect Dis*, doi:10.1093/cid/ciaa344 (2020).
- 438 24 Li, X. Y. *et al.* [The keypoints in treatment of the critical coronavirus disease 2019 patient(2)].
439 *Zhonghua Jie He He Hu Xi Za Zhi* **43**, 277-281, doi:10.3760/cma.j.cn112147-20200224-
440 00159 (2020).
- 441 25 Zeng, Q. L. *et al.* Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in
442 COVID-19 Patients. *J Infect Dis*, doi:10.1093/infdis/jiaa228 (2020).
- 443 26 Bonilla, F. A. & Oettgen, H. C. Adaptive immunity. *J Allergy Clin Immunol* **125**, S33-40,
444 doi:10.1016/j.jaci.2009.09.017 (2010).
- 445 27 Cao, X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* **20**,
446 269-270, doi:10.1038/s41577-020-0308-3 (2020).
- 447 28 Berry, J. D. *et al.* Neutralizing epitopes of the SARS-CoV S-protein cluster independent of
448 repertoire, antigen structure or mAb technology. *MAbs* **2**, 53-66, doi:10.4161/mabs.2.1.10788
449 (2010).
- 450 29 Johnson, R. F. *et al.* 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung
451 pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-
452 n3/2012. *Virology* **490**, 49-58, doi:10.1016/j.virol.2016.01.004 (2016).
- 453 30 Qiu, M. *et al.* Antibody responses to individual proteins of SARS coronavirus and their
454 neutralization activities. *Microbes Infect* **7**, 882-889, doi:10.1016/j.micinf.2005.02.006 (2005).
- 455 31 Thomson, C. A., Little, K. Q., Reason, D. C. & Schrader, J. W. Somatic diversity in CDR3
456 loops allows single V-genes to encode innate immunological memories for multiple
457 pathogens. *J Immunol* **186**, 2291-2298, doi:10.4049/jimmunol.0904092 (2011).
- 458

459 **Methods**

460 **Sample collection and single cell library preparation**

461 This study was approved by the Medical Ethics Committee of Wuhan Infectious
462 diseases hospital, China and the blood samples were collected from patients who had
463 signed the informed consent. The Human Peripheral Blood Mononuclear Cells (PBMCs)
464 were obtained by Ficoll density gradient centrifugation (DakeweBiotech) according to
465 the manufacturer's instruction and then applied to the red blood cell lysis solution
466 (Miltenyi Biotec) for 10 minutes at room temperature. Following washing steps with
467 PBS containing 2% FBS, T cells were isolated from PBMCs using human CD3
468 microbeads (Miltenyi Biotec) and B cells were isolated using human CD19 microbeads
469 (Miltenyi Biotec). Briefly, PBMCs were filtered using 30 μ m nylon mesh (BD
470 bioscience), mixed with CD3 and CD19 MicroBeads for 15 minutes at 4 °C and applied
471 onto MACS column, respectively. After washing the column on MACS rack with
472 MACS buffer, the columns were removed from the rack and the targeted T cells were
473 eluted from the columns using PBS. Then the sorted B cells and T cells were
474 immediately used for single cell RNA and V(D)J library preparation using Chromium
475 Single Cell V(D)J Reagent Kits (10X Genomics) according to the manuals.

476

477 **ScRNA-seq data preprocessing**

478 The raw sequencing data were aligned, quantified, called, and aggregated using the Cell
479 Ranger Single-Cell Software Suite (version 3.1.0, 10x Genomics) count against the
480 GRCh38 human reference genome with default parameters. The gene-cell counts
481 matrix for the different batches of samples were aggregated by cell ranger by aggr with
482 sequencing batch correction function on. Cells that passed the following filtration were
483 kept for downstream analysis: gene number between 200 and 5000; UMI counts above
484 1000; percentage of UMIs from mitochondrial genes below 10% and that from
485 hemoglobin genes below 1%, respectively.

486

487 **Dimension reduction and clustering**

488 Scanpy³²(V1.4.4) package was used to perform preprocessing of the scRNA-Seq data.

489 The filtered gene-cell matrix was normalized to 10^4 molecules per cell for sequencing
490 depth with `normalize_total` function and log transformed with `log1p` function. The data
491 variation caused by number of obtained UMI counts and percentage of UMIs from
492 Mitochondrial was regressed out with the `regress_out` function. We obtained 1520
493 variable genes with mean expression ranging from 0.0125 and 3 and dispersion greater
494 than 0.5. Uniform manifold approximation and projection (UMAP)³³ was performed
495 with the first 50 principal components from principal component analysis (PCA) for
496 visualization of the single cells. Cell clustering was performed by Leiden algorithm³⁴
497 (faster than Louvain algorithm and uncovers better cell partition) with resolution 1.8.
498 39 clusters were identified in total, among which cluster 0 and 25 were highly
499 resembling each other according to our following cluster analysis. Therefore, we
500 combined cluster 0 and 25 into one cluster labeled as cluster 0 throughout the analysis
501 in this work.

502

503 **Differentially expressed genes (DEGs) analysis for single cell group**

504 DEGs analysis between cell types/subject group/cell clusters was performed by
505 Wilcoxon rank-sum test with `FindAllMarkers` function in Seurat³⁵ (V3.0) with default
506 parameters. Genes with expression natural log fold change > 0.5 and Bonferroni
507 correction adjusted p value < 0.01 were reported as significant DEGs. The top 300
508 genes ordered by absolute value of natural log fold change will be regarded as marker
509 genes for a cell group if there are too many reported significant DEGs. Enrichment
510 analysis of the marker genes were performed with Metascape³⁶ (<https://metascape.org>).

511

512 **Single cell development trajectory reconstruction**

513 The Monocle 3 package(V3.2.0) were applied to construct single cell pseudo-time
514 trajectory to discover differentiating transitions^{12,37,38}. We used highly variable genes
515 identified by Seurat to sort cells in pseudo-time order. The actual precursor determined
516 the beginning of pseudo-time in the first round of “`orderCells`”. UMAP was applied to
517 reduce dimensional space and the minimum spanning tree on cells was plotted by the
518 visualization functions “`plot_cells`” for Monocle 3.

519

520 **Cell-cell communication**

521 Cell–cell communication was predicted by a method similar to that described by
522 Kirouac et al^{39,40}. We created a cell-cell communication interactome with known
523 protein-protein interactions between receptor and ligand collected by Rubin et al.⁴⁰. The
524 involved gene list was further manually filtered with the DEGs of different states in our
525 cell types. To investigate state-related perturbations in these putative cell–cell
526 interaction networks, DEGs metrics (e.g., fold change, p value) from the MAST
527 analysis in Seurat were used to build subnetworks for each set of interactions between
528 cell types. In these networks, nodes represent ligands or receptors expressed in the
529 denoted cell type, and edges represent protein–protein interactions between them.
530 Nodes were colored to represent the magnitude of DGE. These values were scaled per
531 cell type and summed to determine edge weight.

532

533 We used CellPhoneDB V2.0⁴¹ to calculate ligand-receptor interactions between T cells
534 and B cells in different states. We used the sequencing depth normalized raw UMI
535 counts as input into “cellphonedb method statistical_analysis” to analyze the dataset
536 and select the significant pairs of ligand-receptor to plot.

537

538 **Evaluation of cytokine expression level in specific cell type across subject groups**

539 We curated a list of genes that can produce cytokine, including chemokine, TNF,
540 interferon and interleukin, which can potentially reflect the level of cytokine storm in
541 the patients. For each cell type in each subject group, we applied a similar strategy to
542 aggregate expression level and expression fraction in a cell population proposed by
543 Peng et al., 2019⁴² and calculated two matrices E and F . For each gene g and a cell type
544 in a subject group cg , $E(g, cg)$ is the mean expression of cells with positive expression
545 and $F(g, cg)$ is the fraction of cells in a cell group cg that have positive number of UMIs
546 of g . The evaluation expression score for each gene in each cell type of each subject
547 group is calculated as the product of the two matrices: $Score = E * F$. Then we visualized
548 this score with bubble matrix plot.

549

550 **TCR/BCR V(D)J sequencing and analysis**

551 TCR/BCR V(D)J segments were enriched from amplified cDNA from 5' libraries via
552 PCR amplification using a Chromium Single-Cell V(D)J Enrichment kit according to
553 the manufacturer's protocol (10x Genomics). The FATAQ files for each single T cell
554 were assembled by Cell Ranger vdj pipeline (v3.1.0), calling to the identification of
555 CDR3 sequence and the rearranged V(D)J gene.

556 In order to get the dominant TCR/BCR of a single cell, we filtered a total of 70,996
557 high-confidence contig sequences in cell barcodes as follows: 1) kept the barcodes
558 which was productive and marked as raw clonotype. 2) only TCR alpha-beta (TRA-
559 TRB, we dropped slight number of TRA-TRG) or BCR heavy-light (IGH-IGL, IGH-
560 IGK) paired chain were considered. 3) if more than one TCR/BCR paired chains were
561 identified in one cell, we only kept the dominant paired chain (supported by largest
562 number of UMIs) for it. Finally, we got a total of 57,932 cells with paired chain
563 information (16,745 T lymphocytes and 41,187 B lymphocytes). A unique clonotype
564 was defined by consistent CDR3 amino acid sequence, V gene and J gene. Chao1
565 repertoire diversity⁴³ and repertoire overlap analysis was estimated by VDJtools⁴⁴. We
566 used immunarch(V0.5.5)⁴⁵ to compute gene usage against IMGT database
567 (<http://www.imgt.org/IMGTrepertoire/LocusGenes/>). TCR clonotypes was annotated with
568 VDJdb⁴⁶ antigen categories database.

569

570 **Data availability**

571 The scRNA-seq data and V(D)J sequencing data used in this study have been deposited
572 in the GSA (Genome Sequence Archive in BIG Data Center, Beijing Institute of
573 Genomics, Chinese Academy of Sciences).

574

575

576 **References in methods**

577

578 32 Wolf, F. A., Angerer, P. & Theis, F. J. J. G. b. SCANPY: large-scale single-cell gene
579 expression data analysis. **19**, 15 (2018).

- 580 33 McInnes, L., Healy, J. & Melville, J. J. a. p. a. Umap: Uniform manifold approximation and
581 projection for dimension reduction. (2018).
- 582 34 Traag, V. A., Waltman, L. & van Eck, N. J. J. S. r. From Louvain to Leiden: guaranteeing
583 well-connected communities. **9**, 1-12 (2019).
- 584 35 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. J. N. b. Integrating single-cell
585 transcriptomic data across different conditions, technologies, and species. **36**, 411-420
586 (2018).
- 587 36 Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-
588 level datasets. **10**, 1-10 (2019).
- 589 37 Qiu, X. *et al.* Single-cell mRNA quantification and differential analysis with Census. *Nat*
590 *Methods* **14**, 309-315, doi:10.1038/nmeth.4150 (2017).
- 591 38 Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by
592 pseudotemporal ordering of single cells. *Nat Biotechnol* **32**, 381-386, doi:10.1038/nbt.2859
593 (2014).
- 594 39 Kirouac, D. C. *et al.* Dynamic interaction networks in a hierarchically organized tissue. *Mol*
595 *Syst Biol* **6**, 417, doi:10.1038/msb.2010.71 (2010).
- 596 40 Ximerakis, M. *et al.* Single-cell transcriptomic profiling of the aging mouse brain. *Nat*
597 *Neurosci* **22**, 1696-1708, doi:10.1038/s41593-019-0491-3 (2019).
- 598 41 Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB:
599 inferring cell-cell communication from combined expression of multi-subunit ligand-receptor
600 complexes. *Nat Protoc* **15**, 1484-1506, doi:10.1038/s41596-020-0292-x (2020).
- 601 42 Peng, Y.-R. *et al.* Molecular classification and comparative taxonomics of foveal and
602 peripheral cells in primate retina. **176**, 1222-1237. e1222 (2019).
- 603 43 Colwell, R. K. *et al.* Models and estimators linking individual-based and sample-based
604 rarefaction, extrapolation and comparison of assemblages. **5**, 3-21 (2012).
- 605 44 Shugay, M. *et al.* VDJtools: unifying post-analysis of T cell receptor repertoires. **11** (2015).
- 606 45 Team, I. (<http://doi.org/10.5281/zenodo.3383240>, 2019).
- 607 46 Bagaev, D. V. *et al.* VDJdb in 2019: database extension, new analysis infrastructure and a T-
608 cell receptor motif compendium. **48**, D1057-D1062 (2020).

609

610

611

612

613

614

615

616

617

618 **Figure Legend**

619 **Figure 1. Cell type characterization of PBMCs in COVID-19 patients and normal**
620 **controls**

- 621 a. A total of 70,984 cells enriched with CD3 and CD19 antibodies were divided into
622 38 clusters, which were categorized into 18 cell types. The numbers in the brackets are
623 the corresponding clusters for each cell type.
- 624 b. Feature plot showing the identical markers for general cell types: *CD3E* is a general
625 marker for T lymphocytes, which are further divided into *CD4+* and *CD8+* T
626 lymphocytes. *CD19* and *CD79A* represent B cells; *CD14* is a marker for monocytes;
627 *FCERIA+* represents dendritic cells; PPBP represents platelets.
- 628 c. Histograms showing the relationships of the 38 clusters and marker genes for each
629 cell type are shown with violin plots in each cluster.
- 630 d. UMAP showing the cell type distribution of the four groups (healthy, RE, RL and
631 severe) of patients.
- 632 e. Bar plot showing the compositions of each cell type in healthy, RE, RL and severe
633 patients.

634

635 **Figure 2. Novel cell subtypes and distinct gene regulation in COVID-19 patients**

- 636 a. Heatmap showing the patient group DEGs in T lymphocytes.
- 637 b. Identical GO terms enriched in the T lymphocytes of RE, RL and severe patients.
- 638 c. UMAP showing the cell types of T lymphocytes and their patient group identities.
- 639 d. Feature plot showing the patient group DEGs and cell type markers.
- 640 e. Monocle map showing the differentiation of CD8 T cells upon SARS-CoV-2
641 infection. The patient group compositions for each cluster of CD8 T cells are shown by
642 a pie chart.
- 643 f. Heatmap showing the DEGs of effector CD8 T cells among healthy, RE, RL and
644 severe patients.
- 645 g. Feature plot of patient group-specific effector CD8 T cell genes on the monocle
646 map, reflecting different stages of effector CD8 T cell differentiation in each group of
647 patients.
- 648 h. Heatmap showing the DEGs between the types of CD4 T cells. Representative
649 genes and GO terms are shown on the right.
- 650 i. Dot plots showing the expression of identical genes in subtypes of monocytes. The
651 patient group compositions for each cluster are shown by the pie chart on the top.
- 652 j. Ligand and receptor communication analysis of Th1 and *CD14+* monocytes
653 between severe patients and other groups.
- 654 k. Correlation of clusters of B lymphocytes based on gene expression patterns.
- 655 l. Bar plot showing the composition of healthy, RE, RL and severe patients in the
656 clusters of k.
- 657 m. Feature plot showing the identical genes specifying B cell states and subtypes.
- 658 n. Heatmap showing the DEGs of effector B cells among healthy, RE, RL and severe
659 patients.
- 660 o. Representative GO terms of group-specific genes in n.

661

662 **Figure 3. BCR and TCR clone expansion in COVID-19 patients**

- 663 a. Calculation of expanded clone ratios of BCRs and TCRs in healthy, RE, RL and
664 severe patients.
- 665 b. Gene expression correlation analysis among monoclonal B cells and clonally
666 expanded B cells in the four patient groups.
- 667 c. Volcano plot showing the DEGs of monoclonal B cells and clonally expanded B
668 cells in the severe patients. The latter showed a high activation state, expressing genes
669 such as *XBPI*, *MAZB*, *IGLL5*, etc.
- 670 d, e. The frequent VJ gene combinations in BCRs and TCRs within each group of
671 COVID-19 patients.
- 672 f, g. The V and J genes showing high usage frequency in BCRs and TCRs of COVID-
673 19 patients.
- 674 h. TCR clone type tracking showing the enriched CDR3 types (only those types with
675 a clone size >1 are shown here) in healthy, RE, RL and severe patients.

676

677 **Figure 4. Cell type-based BCR and TCR clone expansion in COVID-19 patients**

- 678 a. The clone size distribution of B cell and other cell subtypes in healthy, RE, RL and
679 severe patients.
- 680 b. Feature plot showing the clonally expanded cells and their clone size in effector
681 CD8 T cells, plasmablasts and plasma B cells in healthy, RE, RL and severe patients.
682 The effector CD8 T cells in severe samples showed extreme levels of clonal expansion.
683 The plasmablasts had the highest fraction of cells showing clonal expansion. The
684 plasma B cells in all groups were detected to be clonally expanded. The dark gray dots
685 represent the cells with only one clone detected.
- 686 c. Monocle analysis of plasmablasts and plasma B cells. Several clonotypes
687 supporting the trajectory are shown. These clonotypes were all detected in severe
688 patients.
- 689 d. Volcano plot showing the DEGs of the two clusters of plasma B cells.
- 690 e. Bubble plot showing the major chemokine genes expressed in each cell type of
691 healthy, RE, RL and severe patients.

692

693 **Figure S1. Clustering of single cells using scRNA-seq data**

- 694 a. The 38 clusters of the 70,984 cells from 13 individuals.
- 695 b. Pie chart showing the composition of cell in each group of samples.
- 696 c. Barplot showing the gene number detected in each cell type.

697

698 **Figure S2. Cell types of CD3 and CD19 enriched PBMCs in COVID-19 patients**

- 699 a. Heatmap showing the 18 cell types with specific gene expression patterns.
- 700 b. The enriched GO terms of the cell type DEGs for the 18 cell types.

701

702 **Figure S3. Cell types in each group of patients**

- 703 a. UMAP showing the well replication of cells from different individual patients of
704 the same group.
- 705 b. Pie chart showing the cell type ratios in each group of patients.

706

707 **Figure S4. Clustering of single cells using scRNA-seq data**

- 708 a. Heatmap showing the correlations of the clusters of T lymphocytes.
709 b. Barplot showing the composition of Healthy, RE, RL and Severe patients in the
710 clusters of a.
711 c. Volcano plot showing the DEGs between cluster 8 and cluster 26 naïve CD8 T cells.

712

713 **Figure S5. Subtypes of CD8 T cells and monocytes**

714 Heatmap showing the DEGs between the cell subtypes of CD8 T cells (a) and
715 monocytes (b). Representative GO terms are shown on the right.

716

717 **Figure S6. Subtypes of B cells**

- 718 a. Heatmap showing the DEGs between the cell subtypes of B lymphocytes.
719 Representative GO terms are shown on the right.
720 b. Feature plot showing representative genes of the DEGs in Fig. 2n.
721 c. Interaction of Th2 like Tfh cells (ligand) with B cells in each group of patients.

722

723 **Figure S7. Statistics of BCR and TCR in each group of sample**

- 724 a. The clone counts observed for each strand of BCR and TCR in Healthy, RE, RL and
725 Severe patients.
726 b. The estimated clone diversity in Healthy, RE, RL and Severe patients.

727

728 **Figure S8. Statistics of BCR and TCR in each group of sample**

729 Calculation of expended clone ratios of BCR and TCR in every individual patient of
730 each group.

731

732 **Figure S9. Statistics of BCR and TCR in each group of sample**

733 Feature plot showing the clonal expended cells and their clone size in Naïve CD4 T
734 cells, Naïve CD8 T cells, Effector memory CD 8 T cells, central memory CD 8 T cells
735 and B cells in Healthy, RE, RL and Severe patients. The dark grey dots represent the
736 cells with only one copy of clone detected.

737

738

739

Fig.1




Fig.2




Fig. 3






Fig.4


a




b



c



d



e




Fig. S1




Fig. S2




Fig. S3




Fig. S4




Fig. S5




Fig. S6




Fig. S7




Fig. S8




Fig. S9

